TW200516081A - PTP1B anti-sense compounds - Google Patents

PTP1B anti-sense compounds

Info

Publication number
TW200516081A
TW200516081A TW093125691A TW93125691A TW200516081A TW 200516081 A TW200516081 A TW 200516081A TW 093125691 A TW093125691 A TW 093125691A TW 93125691 A TW93125691 A TW 93125691A TW 200516081 A TW200516081 A TW 200516081A
Authority
TW
Taiwan
Prior art keywords
ptp1b
different
represent same
sense compounds
nonvel
Prior art date
Application number
TW093125691A
Other languages
Chinese (zh)
Inventor
Makoto Koizumi
Kazushi Araki
Ryo Okuyama
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of TW200516081A publication Critical patent/TW200516081A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03048—Protein-tyrosine-phosphatase (3.1.3.48)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A Nonvel PTP1B antisense compound and pharmacologically acceptable salt thereof of formula E1-B1-B2-B3-B4-B5-B6-B7-B8-B9-B10-B11-B12-B13-B14-B15-B16-E2 (l) (wherein, B1, B4, B5, B10, B13 and B16 represent same or different Tp and the lice, B11 represents Gp and the like, B2, B3, B6, B7, B9﹑B14, B15 represent same or different Cp and the like, B8, B12 represent same or different Ap and the like. E1 represents hydrogen group and the like, and E2-B23-R1 and the like) which inhibits the activity of PTPIB, and effectively treats the disease concerned with hyperactivity of tyrosine phosphorylation due to PTP1B.
TW093125691A 2003-08-28 2004-08-27 PTP1B anti-sense compounds TW200516081A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2003304489 2003-08-28

Publications (1)

Publication Number Publication Date
TW200516081A true TW200516081A (en) 2005-05-16

Family

ID=34269271

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093125691A TW200516081A (en) 2003-08-28 2004-08-27 PTP1B anti-sense compounds

Country Status (2)

Country Link
TW (1) TW200516081A (en)
WO (1) WO2005021572A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020055479A1 (en) 2000-01-18 2002-05-09 Cowsert Lex M. Antisense modulation of PTP1B expression
US7179796B2 (en) 2000-01-18 2007-02-20 Isis Pharmaceuticals, Inc. Antisense modulation of PTP1B expression
EP2697244B1 (en) 2011-04-13 2017-05-17 Ionis Pharmaceuticals, Inc. Antisense modulation of ptp1b expression

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2489145A1 (en) * 2002-05-24 2003-12-04 Takeda Pharmaceutical Company Limited Insulin-sensitizing agent

Also Published As

Publication number Publication date
WO2005021572A1 (en) 2005-03-10

Similar Documents

Publication Publication Date Title
MY140638A (en) New heterocyclic compounds, which are active as inhibitors of beta-lactamases
MX2007013624A (en) Protein kinase inhibitors.
TW200626068A (en) Active compounds for seed treatment
TW200740434A (en) A prophylactic and/or therapeutic agent for for sleep disorders
NO20062689L (en) Azabicyclic heterocycles as modulators of cannabinoid receptors
WO2008005956A3 (en) Pyrrolotriazine kinase inhibitors
IL179607A0 (en) Indoles useful in the treatment of inflammation
MY153044A (en) Tetrahydroquinoline derivatives for treating post-traumatic stress disorders
UA84460C2 (en) Use of sulphonylcarbamides for combating undesirable plant growth in leguminous plant cultures
MX2009005691A (en) Inhibitors of diacylglycerol o-acylotransferase type 1 enzyme.
IL179728A0 (en) Indoles useful in the treatment of inflammation
MX2009002735A (en) Oxindole derivatives.
DE602007011414D1 (en) AGRICULTURAL CHEMICAL COMPOSITIONS WITH ALKYLENDIOL-MODIFIED POLYSILOXANES
BRPI0810641A2 (en) "pharmaceutical compounds".
TW200744586A (en) Therapeutic compounds
HK1091481A1 (en) Therapeutic agents useful for treating pain
MX2010004312A (en) Spiro-condensed 1, 3, 4-thiadiazole derivatives for inhibiting ksp kinesin activity.
GEP20125538B (en) 2,3-dihydrobenzo(1,4) dioxin-2-ylmethyl derivatives as alpha2c antagonists for use in the treatment of peripheric and central nervous system diseases
MY151295A (en) Pyrimidyl indoline compound
BRPI0410649A (en) substituted benzo (b) thiophene 3-aryloxy and 3-heteroaryloxy as therapeutic agents with pi3k activity
WO2006127379A3 (en) Par2-modulating compounds and their use
PA8599701A1 (en) DOSAGE FORMS AND TREATMENT PROCEDURES USING VEGFR INHIBITORS
NO20092035L (en) Thiazolyl compounds useful as kinase inhibitors
TW200516081A (en) PTP1B anti-sense compounds
TW200736236A (en) Process for the manufacturing of pharmaceutically active compounds